Company Data

PDS Biotechnology Corporation

Fundamental Analysis:
ā€Œ
PDS Biotechnology Corporation
ā€Œ
PDS Biotechnology Corporation
Fundamental Analysis:
Ticker
PDSB
Current Price
$3.42 3.32%
Market Cap
$125.9M
Price Target
Refer to Report
Volume
166.4K
52wk Range
$2.53 - $6.85
Advanced Market Data

Overview

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary VersamuneĀ®Ā and Infectimuneā„¢ T cell-activating technology platforms. We believe our targeted VersamuneĀ®Ā based candidates have the potential to overcome the limitations of current immunotherapy by inducing large quantities of high-quality, potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. To date, our lead VersamuneĀ®Ā clinical candidate, PDS0101, has demonstrated the potential to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV-positive cancers in multiple Phase 2 clinical trials. Our Infectimuneā„¢ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visitĀ www.pdsbiotech.comĀ or follow us on Twitter at @PDSBiotech.

Inbox Intel from Channelchek.

Informed investors make more money. And itā€™s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy